Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $7.7143.

A number of equities research analysts have commented on the company. BTIG Research decreased their price objective on Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Wall Street Zen lowered Humacyte from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. Benchmark reduced their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 21st. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Friday, March 27th.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently made changes to their positions in the company. R Squared Ltd acquired a new stake in shares of Humacyte during the 4th quarter valued at about $25,000. Atom Investors LP acquired a new stake in shares of Humacyte during the 4th quarter valued at about $25,000. Truist Financial Corp acquired a new stake in shares of Humacyte during the 3rd quarter valued at about $28,000. Prudential Financial Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at about $28,000. Finally, Financial Advisors Network Inc. acquired a new stake in shares of Humacyte during the 2nd quarter valued at about $28,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Trading Up 0.7%

Shares of NASDAQ HUMA opened at $0.65 on Wednesday. Humacyte has a one year low of $0.55 and a one year high of $2.93. The firm has a market capitalization of $144.31 million, a PE ratio of -3.25 and a beta of 2.11. The company has a current ratio of 3.69, a quick ratio of 2.95 and a debt-to-equity ratio of 20.08. The business has a 50-day moving average price of $0.96 and a two-hundred day moving average price of $1.21.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). Humacyte had a negative return on equity of 990.48% and a negative net margin of 1,998.87%.The firm had revenue of $0.47 million during the quarter, compared to analyst estimates of $1.35 million. As a group, analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.